Hyaluronidase (Keraform) - ISTA
Alternative Names: KeraformLatest Information Update: 03 Dec 2021
At a glance
- Originator ISTA Pharmaceuticals
- Class Antineoplastics; Glycoside hydrolases; Polysaccharide lyases
- Mechanism of Action Hyaluronic acid modulators; Hyaluronidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Keratoconus
Most Recent Events
- 22 Feb 2005 Suspended - Preclinical for Keratoconus in USA (Ophthalmic)
- 24 Jul 2003 No development reported - Preclinical for Keratoconus in USA (Ophthalmic)
- 29 May 2000 Preclinical development for Keratoconus in USA (Ophthalmic)